(Reuters) - The group released the memo one day after researchers
reported Avandia, or rosiglitazone, raises the risk of
cardiovascular-related death by 64 percent and the risk of
heart attack by 43 percent.
Glaxo strongly objected to the results and defended use of
the drug, which treats type 2 diabetes.
Read more at Reuters.com Government Filings News
reported Avandia, or rosiglitazone, raises the risk of
cardiovascular-related death by 64 percent and the risk of
heart attack by 43 percent.
Glaxo strongly objected to the results and defended use of
the drug, which treats type 2 diabetes.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment